Cost of Revenue Comparison: AstraZeneca PLC vs Pfizer Inc.

Cost of Revenue: AstraZeneca vs. Pfizer

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, AstraZeneca PLC and Pfizer Inc. have shown distinct trends in their cost of revenue. AstraZeneca's costs remained relatively stable, averaging around $6.7 billion annually, with a notable spike in 2021 and 2022, reaching nearly double their previous years. This surge coincides with the global demand for COVID-19 vaccines, highlighting AstraZeneca's strategic pivot during the pandemic.

Conversely, Pfizer's cost of revenue consistently outpaced AstraZeneca's, averaging $16.8 billion annually. The most significant increase occurred in 2021 and 2022, with costs soaring to over $30 billion, reflecting Pfizer's dominant role in vaccine production. By 2023, Pfizer's costs slightly decreased but remained substantially higher than AstraZeneca's, underscoring its expansive market reach and production scale.

These insights reveal the dynamic nature of pharmaceutical giants adapting to global health challenges.